Advanced

Prevention of otitis media: Now a reality?

Schuerman, Lode; Borys, Dorota; Hoet, Bernard; Forsgren, Arne LU and Prymula, Roman (2009) In Vaccine 27(42). p.5748-5754
Abstract
Acute otitis media (AOM), one of the most common childhood diseases, is associated with a substantial medical, social and economic burden. Non-typeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae are the two main causes of bacterial OM. The 7-valent pneumococcal CRM197-conjugate vaccine (7vCRM, Prevnar (TM)/Prevenar (TM), Wyeth) demonstrated efficacy against AOM caused by vaccine pneumococcal serotypes. Protection against overall AOM was also observed with an 11-valent pneumococcal protein D-conjugate vaccine (11Pn-PD) in the Pneumococcal Otitis EfficacyTrial (POET). Following POET, an optimized 10-valent pneumococcal non-typeable H. influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix (TM), GlaxoSmithlKline... (More)
Acute otitis media (AOM), one of the most common childhood diseases, is associated with a substantial medical, social and economic burden. Non-typeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae are the two main causes of bacterial OM. The 7-valent pneumococcal CRM197-conjugate vaccine (7vCRM, Prevnar (TM)/Prevenar (TM), Wyeth) demonstrated efficacy against AOM caused by vaccine pneumococcal serotypes. Protection against overall AOM was also observed with an 11-valent pneumococcal protein D-conjugate vaccine (11Pn-PD) in the Pneumococcal Otitis EfficacyTrial (POET). Following POET, an optimized 10-valent pneumococcal non-typeable H. influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix (TM), GlaxoSmithlKline Biologicals) was developed. This vaccine includes serotypes 1, 5, and 7F, in addition to those already included in 7vCRM, and was recently licensed in Europe for active immunization against invasive disease and AOM caused by S. pneumoniae in infants and children from 6 weeks up to 2 years of age. The use of protein D as carrier protein permits avoidance of possible interferences known to occur with some conjugate vaccines, and has the added potential benefit of providing protection against NTHi. This review seeks to highlight the recent advances in the field of OM vaccination, with a focus on data regarding the recently licensed PHiD-CV. (C) 2009 Published by Elsevier Ltd. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Otitis media, influenzae (NTHi), Non-typeable Haemophilus, Protein D, Invasive pneumococcal disease, Pneumococcal conjugate vaccine, Streptococcus pneumoniae
in
Vaccine
volume
27
issue
42
pages
5748 - 5754
publisher
Elsevier
external identifiers
  • wos:000270469900008
  • scopus:69849108072
ISSN
1873-2518
DOI
10.1016/j.vaccine.2009.07.070
language
English
LU publication?
yes
id
c3d76265-a365-48d9-8c0e-e7d868dc30c3 (old id 1488449)
date added to LUP
2009-10-22 12:07:36
date last changed
2017-03-26 03:26:17
@article{c3d76265-a365-48d9-8c0e-e7d868dc30c3,
  abstract     = {Acute otitis media (AOM), one of the most common childhood diseases, is associated with a substantial medical, social and economic burden. Non-typeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae are the two main causes of bacterial OM. The 7-valent pneumococcal CRM197-conjugate vaccine (7vCRM, Prevnar (TM)/Prevenar (TM), Wyeth) demonstrated efficacy against AOM caused by vaccine pneumococcal serotypes. Protection against overall AOM was also observed with an 11-valent pneumococcal protein D-conjugate vaccine (11Pn-PD) in the Pneumococcal Otitis EfficacyTrial (POET). Following POET, an optimized 10-valent pneumococcal non-typeable H. influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix (TM), GlaxoSmithlKline Biologicals) was developed. This vaccine includes serotypes 1, 5, and 7F, in addition to those already included in 7vCRM, and was recently licensed in Europe for active immunization against invasive disease and AOM caused by S. pneumoniae in infants and children from 6 weeks up to 2 years of age. The use of protein D as carrier protein permits avoidance of possible interferences known to occur with some conjugate vaccines, and has the added potential benefit of providing protection against NTHi. This review seeks to highlight the recent advances in the field of OM vaccination, with a focus on data regarding the recently licensed PHiD-CV. (C) 2009 Published by Elsevier Ltd.},
  author       = {Schuerman, Lode and Borys, Dorota and Hoet, Bernard and Forsgren, Arne and Prymula, Roman},
  issn         = {1873-2518},
  keyword      = {Otitis media,influenzae (NTHi),Non-typeable Haemophilus,Protein D,Invasive pneumococcal disease,Pneumococcal conjugate vaccine,Streptococcus pneumoniae},
  language     = {eng},
  number       = {42},
  pages        = {5748--5754},
  publisher    = {Elsevier},
  series       = {Vaccine},
  title        = {Prevention of otitis media: Now a reality?},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2009.07.070},
  volume       = {27},
  year         = {2009},
}